BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26105798)

  • 1. Guidelines are advantageous, though not essential for improved survival among breast cancer patients.
    Wolters R; Wischhusen J; Stüber T; Weiss CR; Krockberger M; Bartmann C; Blettner M; Janni W; Kreienberg R; Schwentner L; Novopashenny I; Wischnewsky M; Wöckel A; Diessner J
    Breast Cancer Res Treat; 2015 Jul; 152(2):357-66. PubMed ID: 26105798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients.
    Wolters R; Wöckel A; Janni W; Novopashenny I; Ebner F; Kreienberg R; Wischnewsky M; Schwentner L;
    Breast Cancer Res Treat; 2013 Dec; 142(3):579-90. PubMed ID: 24258258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of guideline-compliant therapy on the survival of primary breast cancer patients with: results of a retrospective cohort study].
    Wolters R; Wöckel A; Wischnewsky M; Kreienberg R
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(6):468-75. PubMed ID: 21843852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study.
    Wöckel A; Varga D; Atassi Z; Kurzeder C; Wolters R; Wischnewsky M; Wulff C; Kreienberg R
    Onkologie; 2010; 33(1-2):21-8. PubMed ID: 20164658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is guideline-adherent adjuvant treatment an equal alternative for patients aged >65 who cannot participate in adjuvant clinical breast cancer trials? A retrospective multi-center cohort study of 4,142 patients.
    Van Ewijk R; Wöckel A; Gundelach T; Hancke K; Janni W; Singer S; Kreienberg R; Blettner M; Schwentner L
    Arch Gynecol Obstet; 2015 Mar; 291(3):631-40. PubMed ID: 25178186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: An evaluation of 8323 patients.
    Kreienberg R; Wöckel A; Wischnewsky M
    Breast; 2018 Aug; 40():54-59. PubMed ID: 29698925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients.
    Schwentner L; Van Ewijk R; Kurzeder C; Hoffmann I; König J; Kreienberg R; Blettner M; Wöckel A
    Eur J Cancer; 2013 Feb; 49(3):553-63. PubMed ID: 22959469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects.
    Wöckel A; Wolters R; Wiegel T; Novopashenny I; Janni W; Kreienberg R; Wischnewsky M; Schwentner L;
    Ann Oncol; 2014 Mar; 25(3):628-632. PubMed ID: 24515935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients.
    Schwentner L; Wolters R; Wischnewsky M; Kreienberg R; Wöckel A
    Breast; 2012 Apr; 21(2):171-7. PubMed ID: 21945313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients.
    Ebner F; van Ewijk R; Wöckel A; Hancke K; Schwentner L; Fink V; Kreienberg R; Janni W; Blettner M
    Breast; 2015 Jun; 24(3):256-62. PubMed ID: 25769974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
    Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
    Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of guideline adherence in primary breast cancer--a 5-year multi-center cohort study of 3976 patients.
    Wöckel A; Kurzeder C; Geyer V; Novasphenny I; Wolters R; Wischnewsky M; Kreienberg R; Varga D
    Breast; 2010 Apr; 19(2):120-7. PubMed ID: 20117932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients.
    Wollschläger D; Meng X; Wöckel A; Janni W; Kreienberg R; Blettner M; Schwentner L
    Breast J; 2018 Mar; 24(2):120-127. PubMed ID: 28685896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival.
    Beinart G; Gonzalez-Angulo AM; Broglio K; Mejia J; Ruggeri A; Mininberg E; Hortobagyi GN; Valero V
    Clin Breast Cancer; 2007 Dec; 7(11):867-74. PubMed ID: 18269777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
    Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
    Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive Intrinsic Subtypes in Breast Cancer: A Predictor of Guideline Adherence in Older Patients With Breast Cancer?
    Ebner F; Hancke K; Blettner M; Schwentner L; Wöckel A; Kreienberg R; Janni W; van Ewijk R
    Clin Breast Cancer; 2015 Aug; 15(4):e189-95. PubMed ID: 25913904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
    Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?
    Regierer AC; Wolters R; Kurzeder C; Wöckel A; Novopashenny I; Possinger K; Wischnewsky MB; Kreienberg R
    Breast Cancer Res Treat; 2011 Jul; 128(1):273-81. PubMed ID: 21210206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality outcome among medically underserved women screened through a publicly funded breast cancer control program, 1997-2007.
    Bhuyan SS; Stimpson JP; Rajaram SS; Lin G
    Breast Cancer Res Treat; 2014 Jul; 146(1):221-7. PubMed ID: 24903224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.